EMA Grants Orphan Drug Status to Unasnemab for ALS Treatment

The European Medicines Agency has designated Unasnemab, a potential treatment for Amyotrophic Lateral Sclerosis (ALS), as an orphan medicine. This status is granted to drugs developed for rare diseases, aiming to encourage their research and development. The designation supports efforts to bring new therapies to patients with conditions like ALS.